Cutaneous sensitivity to atracurium and vecuronium in patients suffering anaphylactoid reactions to neuromuscular blockers.
Using an ordinal measure of cutaneous sensitivity to intradermal injections of atracurium and vecuronium, 40 nonreacting subjects were compared with a group of 24 patients previously suffering life-threatening anaphylactoid reactions to other muscle relaxants. Enhanced cutaneous sensitivity to vecuronium was found in three, and to atracurium in two of the previously reacting group. With the exception of those showing abnormal reactivity, no significant difference was found in the distribution of cutaneous sensitivity in the control and reacting group. A concentration of vecuronium 8.75 times that of atracurium was required to produce an equivalent intradermal wheal response.
Galletly
D C
DC
Treuren
B C
BC
D000707:Anaphylaxis / Q000139:chemically induced / Q000517:prevention & control*; D001279:Atracurium; D004342:Drug Hypersensitivity / Q000175:diagnosis*; D006801:Humans; D007428:Intradermal Tests; D007546:Isoquinolines / Q000009:adverse effects*; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects*; D010197:Pancuronium / Q000009:adverse effects / Q000031:analogs & derivatives*; D012882:Skin Tests; D014673:Vecuronium Bromide
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D014673:Vecuronium Bromide; D010197:Pancuronium